Pfizer Inc. (NYSE:PFE) Holdings Trimmed by Webster Bank N. A.

Webster Bank N. A. trimmed its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 29.4% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 38,214 shares of the biopharmaceutical company's stock after selling 15,919 shares during the period. Webster Bank N. A.'s holdings in Pfizer were worth $968,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Tallon Kerry Patrick purchased a new stake in shares of Pfizer during the 4th quarter worth $509,000. Brighton Jones LLC increased its stake in Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC raised its holdings in Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after purchasing an additional 2,087 shares in the last quarter. Asset Dedication LLC lifted its position in shares of Pfizer by 107.4% during the 4th quarter. Asset Dedication LLC now owns 26,833 shares of the biopharmaceutical company's stock worth $712,000 after buying an additional 13,896 shares during the last quarter. Finally, Strategic Blueprint LLC boosted its holdings in shares of Pfizer by 2.0% in the fourth quarter. Strategic Blueprint LLC now owns 47,169 shares of the biopharmaceutical company's stock valued at $1,251,000 after acquiring an additional 942 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $25.00 price objective (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Citigroup restated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Finally, UBS Group boosted their price objective on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer currently has an average rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Stock Down 0.1%

Shares of NYSE:PFE traded down $0.04 during trading on Monday, hitting $23.46. The company's stock had a trading volume of 12,049,484 shares, compared to its average volume of 40,977,349. The company has a market capitalization of $133.35 billion, a PE ratio of 16.65, a PEG ratio of 0.64 and a beta of 0.58. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock's 50-day moving average price is $23.12 and its two-hundred day moving average price is $25.05. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same quarter in the previous year, the company posted $0.82 earnings per share. The firm's revenue was down 7.8% on a year-over-year basis. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.33%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.